What a week at JP Morgan Healthcare! Met amazing investors and service providers, fueling Reglagene's journey in developing innovative brain therapies.

We’re proud to share the news that Reglagene has completed a $5.4M private placement of its convertible preferred stock. With the support of our investors and partners, we’re well equipped to take the next steps in the development of our orally administered therapy, RGN6024. Read the full press release below or on the EIN PressWire.

Michael Abrahamson, an alumnus of the R. Ken Coit School of Pharmacy, presented his insights on personal growth and the value of making diverse connections after pharmacy school.

Larry Hecker and Reglagene were both honored at the Governor’s Council on Innovation hosted by AZ Tech Council.

CEO Richard Austin and Director of Operations Michael Abrahamson attended Texas Life Science Forum 2023.

Find out how we were able to enter preclinical development at 10% of the cost in the interview.

Drs. Suzuki, Patrón, and Gokhale present at the AACR Special Conference on Brain Cancer in Minneapolis, MN.

This recognition is a testament to the dedication of our incredible team at Reglagene in advancing therapies for brain diseases. Watch the video to see what drives our commitment to groundbreaking solutions and the future we're building. Thank you, Arizona BioIndustry Association (AZBio)!

Reglagene’s Richard Austin was on a panel during the AZAdvances Innovation Showcase during AZBio Week.